DUBAI, UAE, June 3, 2021 /PRNewswire/ -- Healthcare
solutions provider Global Response Aid (GRA) today reported
seven-month global sales figures for its anti-viral tablet
Avigan®/Reeqonus™, a drug being used in several countries to treat
patients with mild to moderate cases of COVID-19.
"Over the course of a year, GRA has signed a global licensing
agreement for Avigan® with its developer, FujiFilm Toyama, filed a
drug dossier with various regulators, and recently initiated a
global Phase 3 clinical trial in an outpatient setting," said GRA
CEO Mitch Wilson. "Working closely
with our strategic partner Dr. Reddy's, we've taken major steps
toward our goal of providing an affordable, easily administered,
widely available oral anti-viral to help in the fight against this
global pandemic."
Together with Dr. Reddy's Laboratories (NYSE: RDY), GRA is part of a consortium of
companies that has been collaborating on the international
development and distribution of Avigan®/Reeqonus™ for treatment and
prevention of COVID-19 since October
2020. The consortium has generated $33 million in revenue through sales of Avigan®
to pharmaceutical distributors and governments in secondary markets
around the world.
Wilson said the steady increase in sales across a growing number
of countries where Avigan® has been approved to treat COVID-19
"demonstrates that we are not alone in our hope that Avigan® can
contribute in the battle to save lives."
Countries purchasing Avigan® based on regulatory approval of the
therapy for the treatment of COVID-19 include Indonesia, Malaysia, Thailand and India. In a separate deal with FujiFilm, the
Japanese government recently placed an order to stockpile over 65
million tablets.
Avigan® is a broad-spectrum anti-viral in oral tablet form
developed by FujiFilm Toyama Chemical and approved in Japan as a treatment and stockpile
countermeasure for pandemic influenza. Over the past year, the
consortium has collaborated to evaluate Avigan® as an
investigational therapy for early onset COVID-19 patients.
As recently announced by GRA, a Phase 3 US-Canada clinical trial
of the anti-viral yielded a positive interim outlook. The group
will continue evaluating the efficacy of Avigan® for treatment of
patients with mild to moderate cases of COVID-19, and will publish
results in Q3 2021.
About Global Response Aid (GRA)
Agility (KSE/DFM: AGLTY), one of
the world's leading logistics companies and AiPharma, an innovative
pharma research, development and commercialization company based in
Dubai, established Global Response
Aid (GRA) to address the market challenges created by the COVID-19
pandemic and other threats to public health. GRA delivers
innovative, effective healthcare solutions through a range of
pharmaceutical products and technology platforms. It works closely
with governments, regulatory authorities, hospitals, clinics,
healthcare providers, life sciences companies, NGOs and public
institutions to develop strategies that allow them to tackle public
health challenges.
For more information: www.globalresponseaid.com
About Dr. Reddy's
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY)
is an integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through
its three businesses - Pharmaceutical Services & Active
Ingredients, Global Generics and Proprietary Products – Dr. Reddy's
offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy's operates in markets across
the globe. Our major markets include – USA, India,
Russia & CIS countries, and
Europe.
For more information:
www.drreddys.com
About FUJIFILM
FUJIFILM Corporation, Tokyo,
Japan is one of the major operating companies of FUJIFILM
Holdings Corporation. The company brings cutting edge solutions to
a broad range of global industries by leveraging its depth of
knowledge and fundamental technologies developed in its relentless
pursuit of innovation. Its proprietary core technologies contribute
to the various fields including healthcare, graphic systems, highly
functional materials, optical devices, digital imaging and document
products. These products and services are based on its extensive
portfolio of chemical, mechanical, optical, electronic and imaging
technologies. For the year ended March 31,
2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to
responsible environmental stewardship and good corporate
citizenship.
For more information holdings.fujifilm.com
CONTACT:
Mary O'Brien
Chief Marketing Officer
Global Response Aid
mary@globalresponseaid.com
+971 48325557
View original content to download
multimedia:http://www.prnewswire.com/news-releases/global-response-aid-reports-midyear-sales-results-for-covid-drug-301305305.html
SOURCE Global Response Aid